Veeva Systems (NYSE:VEEV) Director Priscilla Hung Sells 750 Shares

Veeva Systems Inc. (NYSE:VEEV) Director Priscilla Hung sold 750 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total value of $195,780.00. Following the completion of the transaction, the director owned 3,242 shares of the company’s stock, valued at approximately $846,291.68. This represents a 18.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Veeva Systems Stock Up 0.5%

NYSE:VEEV opened at $262.30 on Friday. Veeva Systems Inc. has a twelve month low of $148.05 and a twelve month high of $310.50. The firm has a market capitalization of $42.47 billion, a price-to-earnings ratio of 43.14, a price-to-earnings-growth ratio of 1.11 and a beta of 0.97. The stock’s 50 day moving average price is $228.50 and its two-hundred day moving average price is $190.94.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.23 by $0.12. The company had revenue of $927.96 million during the quarter, compared to the consensus estimate of $905.38 million. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%.The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.99 EPS. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, analysts anticipate that Veeva Systems Inc. will post 6.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on VEEV shares. Stifel Nicolaus set a $300.00 price objective on shares of Veeva Systems in a research note on Thursday, August 27th. Wells Fargo & Company reiterated an “overweight” rating and issued a $330.00 target price on shares of Veeva Systems in a research note on Tuesday. TD Cowen lifted their price target on Veeva Systems from $235.00 to $283.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Oppenheimer boosted their price target on Veeva Systems from $225.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, August 17th. Finally, Citigroup upped their price objective on Veeva Systems from $190.00 to $273.00 and gave the company a “neutral” rating in a research note on Friday, August 28th. Nineteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $284.88.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. SHP Wealth Management bought a new stake in shares of Veeva Systems during the fourth quarter worth approximately $26,000. MV Capital Management Inc. bought a new position in shares of Veeva Systems during the fourth quarter worth approximately $30,000. Reflection Asset Management acquired a new stake in Veeva Systems during the 4th quarter worth approximately $32,000. BOK Financial Private Wealth Inc. acquired a new stake in Veeva Systems during the 4th quarter worth approximately $33,000. Finally, Measured Wealth Private Client Group LLC bought a new stake in Veeva Systems in the 3rd quarter valued at $45,000. 88.20% of the stock is owned by institutional investors.

Veeva Systems Company Profile

Veeva Systems Inc is a cloud software company that provides technology solutions for the life sciences industry, including pharmaceutical, biotechnology, medical device and related organizations. Its applications are designed to support functions across the product lifecycle, from research and clinical development through regulatory approval, manufacturing, quality management and commercial operations.

The company’s Veeva Vault platform includes applications for clinical data management, electronic trial management, regulatory information, quality processes, safety operations and commercial content management.